Latanoprost Viatris

Latanoprost, the active ingredient in Latanoprost Viatris, is a prostaglandin analog presented as a sterile ophthalmic solution for intraocular use. It lowers intraocular pressure and is indicated for open‑angle glaucoma and ocular hypertension in adult patients. GNH USA supplies Latanoprost Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost belongs to the prostaglandin analog class and is used to manage conditions that involve elevated intraocular pressure.

Open‑angle glaucoma: reduces intraocular pressure to protect the optic nerve and preserve visual field. Ocular hypertension: lowers eye pressure to reduce the risk of progression to glaucoma.

Latanoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eye irritation or foreign‑body sensation. - Increased eyelash growth (hypertrichosis). - Darkening of the iris or peri‑ocular skin. - Blurred vision: transient changes in visual acuity. - Dry eye sensation.

Serious or Rare Side Effects: - Severe ocular inflammation (uveitis or iritis). - Allergic reactions: swelling, itching, or rash around the eye. - Corneal edema or macular edema affecting vision. - Significant changes in visual acuity or visual field loss. - Ocular infection secondary to compromised ocular surface.

Before prescribing Latanoprost, clinicians should consider several safety aspects.

Monitor intraocular pressure: regular measurements to assess therapeutic response. Assess for ocular infection: ensure the eye is free of active infection before initiation. Avoid use in patients with known hypersensitivity to prostaglandin analogs. Caution in patients with active ocular inflammation or severe dry eye disease. Pregnancy and lactation: safety not established; use only if benefit outweighs potential risk. Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic or systemic agents.

Major Interactions (Avoid): - Concurrent use of other prostaglandin analog eye drops: may increase local side effects. - Combination with systemic carbonic anhydrase inhibitors: additive intraocular pressure lowering may cause hypotony.

Moderate Interactions (Monitor Closely): - Nonsteroidal anti‑inflammatory eye drops: may reduce Latanoprost efficacy. - Beta‑blocker eye drops: additive pressure‑lowering effect requires monitoring. - Topical corticosteroids: may diminish therapeutic response.